Sign in
TerminatedNo phase

Zemedy Application for Irritable Bowel Syndrome

Key facts

Who runs it
Stanford University
Where
Redwood City, United StatesSee the site
Trial code
Status
Terminated
People taking part
21 people enrolled
Started
15 Oct 2021
Ended
8 Mar 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Use of Zemedy Application
Record updated
28 May 2025
Why it stopped
Loss of funding

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Male and female patients >=18 years old
  • Meet Rome IV criteria for IBS for at least 6 months. No restrictions on type of IBS
  • English proficiency (in order to understand use of the application
  • Patient must be on a stable regimen for IBS for at least 30 days
  • Patients must own a smartphone (iOS or Android) in order to participate in the CBT application

Who cannot take part

  • Patient already undergoing cognitive behavioral therapy
  • Active gastrointestinal disease such as Crohn's disease, ulcerative colitis, history of complete colon resection, acute infection, or any disease that precludes participation in CBT application
  • Psychiatric hospitalization within 10 years
  • Current or past diagnosis of a major mental illness such as schizophrenia, bipolar disorder, personality disorder or substance abuse
  • Laboratory or imaging evidence of an alternative explanation of patient's symptoms
  • Active (within the past 3 months) suicidal ideation
  • Prisoners or other detained individuals
  • Adults unable to consent
  • Pregnant people

Where in United States

  • Stanford University School of MedicineRedwood City, United States

About the trial

What the trial wants to find out

The purpose of the study is investigate the effectiveness of Zemedy, a mobile application that enables the digital delivery of a CBT program to people with IBS.

The 2 groups in the trial

  • Control Group (TAU only)No study treatment, for comparison

    Treatment as Usual (TAU) for IBS patients are tailored to each individual's needs and may involve treatment such as: dietary modification, exercise, medication, and anti-diarrheal therapy.

  • Experimental (TAU plus CBT)Treatment being tested

    Subjects who are in the Experimental Group will receive 8 weeks of CBT from the Zemedy mobile application in addition to their treatment as usual (TAU).

    Treatment: Use of Zemedy Application

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Zemedy - Evaluation of Zemedy, a Cognitive Behavioral Therapy-based Digital Therapeutic Application for the Treatment of Irritable Bowel Syndrome
Record updated
28 May 2025